WeVote
Log In

Bill

Bill

SB 271

Prescription Drug Affordability Board; established.

2026 Regular Session Introduced by Jennifer Carroll Foy and 1 co-sponsor

Virginia establishes a Prescription Drug Affordability Board to review and report on drug pricing costs to improve medication accessibility and inform state policy decisions.

Governor's recommendation received by Senate
0
WeVote Research Nonpartisan
Bill Summary · SB 271

Legislative bill overview

SB 271 establishes a Prescription Drug Affordability Board in Virginia with authority to review drug costs and conduct affordability assessments. The board would analyze prescription drug pricing trends and produce reports to inform state policy on medication accessibility and cost management.

Why is this important

Prescription drug costs remain a significant burden for Virginia residents and state healthcare budgets. Creating an affordability review mechanism could help identify problematic pricing patterns and inform future legislative or regulatory action to control costs, though effectiveness depends heavily on the board's enforcement powers and funding.

Potential points of contention

  • Board authority and enforcement: Unclear whether the board can merely recommend action or has power to actually regulate drug prices, which affects real-world impact
  • Industry compliance: Pharmaceutical companies may resist mandatory price reporting or review processes, citing proprietary concerns and potential precedent for price controls
  • Cost-benefit trade-off: Critics may argue oversight boards increase regulatory burden without guaranteeing lower prices, while advocates contend transparency alone creates market pressure for affordability

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.